Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opko Health (OPK), Atea Pharmaceuticals (AVIR) and M...

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals, Inc. ($AVIR) announced an update on their ongoing clinical study. Atea Pharmaceuticals, Inc. (AVIR) is running a Phase 1 stud...

Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atea Pharmaceuticals (AVIR) and Biogen (BIIB) with b...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$5.25	+5.21%	264.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$5.25	+5.2%	264.99K
3
4
5
6

AVIR

AVIR

Get Atea Pharmaceuticals, Inc. Data in Excel

Get Atea Pharmaceuticals, Inc. Data in Excel